CrystalGenomics, Inc. (083790.KQ)
KRW 2545.0
(0.99%)
KRW 2545.0
(0.99%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -30.91 Billion KRW | -34.13% |
| 2022 | -23.04 Billion KRW | -356.35% |
| 2021 | -5.05 Billion KRW | 50.2% |
| 2020 | -10.14 Billion KRW | -557.58% |
| 2019 | -10.56 Billion KRW | 3.83% |
| 2018 | 1.75 Billion KRW | 2.61% |
| 2017 | -6.41 Billion KRW | 0.95% |
| 2016 | -4.08 Billion KRW | 5.5% |
| 2015 | -3.99 Billion KRW | 6.71% |
| 2014 | -7.22 Billion KRW | 3.22% |
| 2013 | -6.03 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -7.51 Billion KRW | -23.16% |
| 2024 Q1 | -6.09 Billion KRW | 57.57% |
| 2023 FY | -30.91 Billion USD | -34.13% |
| 2023 Q1 | -4.31 Billion USD | -744.41% |
| 2023 Q3 | -5.52 Billion USD | 23.34% |
| 2023 Q2 | -7.2 Billion KRW | -66.85% |
| 2023 Q4 | -14.37 Billion USD | -160.28% |
| 2022 FY | -23.04 Billion USD | -356.35% |
| 2022 Q3 | 1.1 Billion USD | 0.0% |
| 2022 Q1 | 785.67 Million USD | 25.35% |
| 2022 Q4 | 669.97 Million USD | -39.3% |
| 2021 Q4 | 626.76 Million USD | -39.79% |
| 2021 FY | -5.05 Billion USD | 50.2% |
| 2021 Q1 | 803.5 Million USD | 30.6% |
| 2021 Q3 | 1.04 Billion USD | 0.0% |
| 2020 Q1 | 566.67 Million USD | 13.33% |
| 2020 Q3 | 1.02 Billion USD | 0.0% |
| 2020 Q4 | 615.22 Million USD | -40.09% |
| 2020 FY | -10.14 Billion USD | -557.58% |
| 2019 Q1 | 547.52 Million USD | 36.87% |
| 2019 Q3 | 773.97 Million USD | 0.0% |
| 2019 FY | 2.21 Billion USD | 3.83% |
| 2019 Q4 | 500.02 Million USD | -35.4% |
| 2018 Q4 | 400.02 Million USD | -44.56% |
| 2018 FY | 2.13 Billion USD | 2.61% |
| 2018 Q3 | 721.53 Million USD | 0.0% |
| 2018 Q1 | 545.76 Million USD | 37.04% |
| 2017 FY | 2.08 Billion USD | 0.95% |
| 2017 Q1 | 529.57 Million USD | 37.92% |
| 2017 Q3 | 707.62 Million USD | 0.0% |
| 2017 Q4 | 398.26 Million USD | -43.72% |
| 2016 FY | 2.06 Billion USD | 5.5% |
| 2016 Q4 | 383.96 Million USD | -45.41% |
| 2016 Q3 | 703.36 Million USD | 0.0% |
| 2016 Q1 | 536.37 Million USD | 40.17% |
| 2015 Q3 | 669.27 Million USD | 0.0% |
| 2015 Q1 | 513.94 Million USD | 25.79% |
| 2015 FY | 1.95 Billion USD | 6.71% |
| 2015 Q4 | 382.66 Million USD | -42.82% |
| 2014 FY | 1.83 Billion USD | 3.22% |
| 2014 Q1 | 478.95 Million USD | 24.82% |
| 2014 Q3 | 630.2 Million USD | 0.0% |
| 2014 Q4 | 408.56 Million USD | -35.17% |
| 2013 Q1 | 456.03 Million USD | 43.6% |
| 2013 Q4 | 383.72 Million USD | -39.6% |
| 2013 FY | 1.77 Billion USD | 0.0% |
| 2013 Q3 | 635.27 Million USD | 0.0% |
| 2012 Q4 | 317.57 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 75.275% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -841.046% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 3065.947% |
| Bioneer Corporation | 791.75 Million KRW | 4004.372% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | -509.262% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | -23.009% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 12.292% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | -227.982% |
| Medy-Tox Inc. | 17.32 Billion KRW | 278.457% |
| Peptron, Inc. | -15.6 Billion KRW | -98.123% |
| Amicogen, Inc. | 2.05 Billion KRW | 1603.446% |
| Genexine, Inc. | -41.24 Billion KRW | 25.043% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | -255.311% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 61.752% |
| ALTEOGEN Inc. | -9.73 Billion KRW | -217.485% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 130.662% |
| SillaJen, Inc. | -21.34 Billion KRW | -44.82% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 1273.774% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | -69.988% |
| Genomictree Inc. | -17.3 Billion KRW | -78.652% |
| MedPacto, Inc. | -28.75 Billion KRW | -7.516% |
| D&D Pharmatech | -13.48 Billion KRW | -129.218% |
| EASY BIO,Inc. | 20.63 Billion KRW | 249.836% |
| GI Innovation, Inc. | -55.6 Billion KRW | 44.405% |